The Future of UK Pharma Post-Brexit Regulations

As the UK separates from EU drug laws, the pharmaceutical sector faces a high-stakes balancing act: align with Brussels, go its own way, or attempt a hybrid. Each path has major implications for drug access, cost, and innovation.

Let’s look at how Britain re-engineered its system for the approvals of medicines during this transition process—and what changes are still pending.